Abramsky O, Teitelbaum D, Arnon R
J Neurol Sci. 1977 Apr;31(3):433-8. doi: 10.1016/0022-510x(77)90220-9.
Three patients with acute disseminated encephalomyelitis (ADE) and 4 patients in the terminal stages of multiple sclerosis (MS) were subjected to treatment with Cop 1, a synthetic copolymer of amino acids, which had previously been shown to have a beneficial effect in the treatment of experimental allergic encephalomyelitis (EAE). Under the treatment, the ADE patients recovered completely within 3 weeks, but 1 of 2 control cases treated with steroids showed complete recovery as well. The MS patients did not show any significant change in their motor function; however, 2 of them showed some improvement in vision and speech capacity. It is too early to conclude whether this improvement is related to the treatment. No side effect was observed in any of the patients treated with Cop. 1.
三名急性播散性脑脊髓炎（ADE）患者和四名多发性硬化症（MS）晚期患者接受了Cop 1治疗，Cop 1是一种氨基酸合成共聚物，此前已证明其在治疗实验性过敏性脑脊髓炎（EAE）方面具有有益作用。在治疗过程中，ADE患者在3周内完全康复，但接受类固醇治疗的2例对照病例中有1例也完全康复。MS患者的运动功能没有明显变化；然而，其中2例患者的视力和言语能力有一定改善。现在得出这种改善是否与治疗有关的结论还为时过早。接受Cop 1治疗的患者均未观察到副作用。
